2024 Q1 Form 10-K Financial Statement
#000095017024018766 Filed on February 22, 2024
Income Statement
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
Revenue | $50.79M | $55.60M | $232.3M |
YoY Change | 8.24% | -69.87% | -67.86% |
Cost Of Revenue | $10.97M | $8.689M | $50.17M |
YoY Change | -25.46% | -88.79% | -80.86% |
Gross Profit | $39.82M | $46.91M | $182.1M |
YoY Change | 23.63% | -56.16% | -60.45% |
Gross Profit Margin | 78.41% | 84.37% | 78.4% |
Selling, General & Admin | $44.07M | $39.79M | $152.9M |
YoY Change | 20.58% | 30.98% | 16.39% |
% of Gross Profit | 110.65% | 84.83% | 83.98% |
Research & Development | $13.53M | $14.12M | $54.89M |
YoY Change | -0.57% | 9.84% | 17.78% |
% of Gross Profit | 33.97% | 30.1% | 30.14% |
Depreciation & Amortization | $1.124M | $1.142M | $4.342M |
YoY Change | 10.96% | 36.44% | 13.9% |
% of Gross Profit | 2.82% | 2.43% | 2.38% |
Operating Expenses | $57.59M | $53.91M | $207.8M |
YoY Change | 14.85% | 24.69% | 16.75% |
Operating Profit | -$17.77M | -$7.005M | -$37.03M |
YoY Change | -41.26% | -110.99% | -113.06% |
Interest Expense | $1.695M | $7.864M | $6.757M |
YoY Change | 0.53% | 197.88% | 0.37% |
% of Operating Profit | |||
Other Income/Expense, Net | $101.0K | $1.623M | -$152.0K |
YoY Change | 339.13% | -26.19% | -236.94% |
Pretax Income | -$11.50M | $996.0K | -$4.367M |
YoY Change | -51.52% | -98.53% | -101.48% |
Income Tax | -$2.800M | $777.0K | $2.022M |
% Of Pretax Income | 78.01% | ||
Net Earnings | -$8.721M | $219.0K | -$6.389M |
YoY Change | -64.16% | -99.68% | -102.18% |
Net Earnings / Revenue | -17.17% | 0.39% | -2.75% |
Basic Earnings Per Share | -$0.07 | -$0.05 | |
Diluted Earnings Per Share | -$0.07 | $0.00 | -$0.05 |
COMMON SHARES | |||
Basic Shares Outstanding | 130.6M | 129.3M | 128.7M |
Diluted Shares Outstanding | 130.2M | 128.7M |
Balance Sheet
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $723.5M | $742.3M | $742.3M |
YoY Change | 10.98% | 18.88% | 18.88% |
Cash & Equivalents | $132.0M | $150.3M | $150.3M |
Short-Term Investments | $591.5M | $592.0M | $592.0M |
Other Short-Term Assets | $19.79M | $19.00M | $19.00M |
YoY Change | 26.64% | -77.82% | -77.82% |
Inventory | $61.81M | $53.29M | $53.29M |
Prepaid Expenses | |||
Receivables | $44.16M | $40.61M | $40.61M |
Other Receivables | $1.993M | $3.926M | $3.926M |
Total Short-Term Assets | $851.3M | $859.1M | $859.1M |
YoY Change | 2.55% | -6.31% | -6.31% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $36.41M | $37.30M | $61.58M |
YoY Change | -4.58% | -0.8% | -2.77% |
Goodwill | $2.022M | $2.067M | |
YoY Change | -0.79% | 3.04% | |
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $73.45M | $74.33M | $74.33M |
YoY Change | -0.66% | 2144.79% | 2012.71% |
Total Long-Term Assets | $135.3M | $138.0M | $138.0M |
YoY Change | -3.22% | 100.36% | 100.36% |
TOTAL ASSETS | |||
Total Short-Term Assets | $851.3M | $859.1M | $859.1M |
Total Long-Term Assets | $135.3M | $138.0M | $138.0M |
Total Assets | $986.6M | $997.1M | $997.1M |
YoY Change | 1.72% | 1.14% | 1.14% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $2.431M | $5.245M | $5.245M |
YoY Change | -66.68% | 63.34% | 63.34% |
Accrued Expenses | $45.84M | $49.45M | $56.93M |
YoY Change | 64.7% | 60.97% | -61.24% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $56.00M | $62.20M | $62.20M |
YoY Change | -38.81% | -58.56% | -58.56% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $223.0M | $222.7M | $222.7M |
YoY Change | 0.51% | 0.51% | 0.51% |
Other Long-Term Liabilities | $203.0K | $74.00K | $90.13M |
YoY Change | -42.33% | -80.73% | 171.6% |
Total Long-Term Liabilities | $203.0K | $74.00K | $312.8M |
YoY Change | -42.33% | -80.73% | 22.79% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $56.00M | $62.20M | $62.20M |
Total Long-Term Liabilities | $203.0K | $74.00K | $312.8M |
Total Liabilities | $368.1M | $375.0M | $375.0M |
YoY Change | -9.38% | -7.36% | -7.36% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$939.3M | -$930.6M | |
YoY Change | -0.97% | 0.69% | |
Common Stock | $1.562B | $1.555B | |
YoY Change | 3.01% | 2.92% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $618.5M | $622.1M | $622.1M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $986.6M | $997.1M | $997.1M |
YoY Change | 1.72% | 1.14% | 1.14% |
Cashflow Statement
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$8.721M | $219.0K | -$6.389M |
YoY Change | -64.16% | -99.68% | -102.18% |
Depreciation, Depletion And Amortization | $1.124M | $1.142M | $4.342M |
YoY Change | 10.96% | 36.44% | 13.9% |
Cash From Operating Activities | -$16.68M | $13.76M | $100.6M |
YoY Change | -160.38% | -60.62% | 60.35% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $749.0K | $1.704M | $4.104M |
YoY Change | -41.62% | 7.37% | -42.51% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $3.580M | -$18.52M | -$149.8M |
YoY Change | -107.01% | -40.97% | -51.49% |
Cash From Investing Activities | $2.831M | -$20.23M | -$153.9M |
YoY Change | -105.41% | -38.64% | -51.29% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $0.00 | ||
YoY Change | |||
Debt Paid & Issued, Net | $0.00 | ||
YoY Change | |||
Cash From Financing Activities | -4.203M | 1.786M | 1.386M |
YoY Change | 36.02% | 1067.32% | -92.9% |
NET CHANGE | |||
Cash From Operating Activities | -16.68M | 13.76M | 100.6M |
Cash From Investing Activities | 2.831M | -20.23M | -153.9M |
Cash From Financing Activities | -4.203M | 1.786M | 1.386M |
Net Change In Cash | -18.25M | -4.679M | -51.66M |
YoY Change | -33.99% | -319.26% | -77.94% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$16.68M | $13.76M | $100.6M |
Capital Expenditures | $749.0K | $1.704M | $4.104M |
Free Cash Flow | -$17.43M | $12.06M | $96.46M |
YoY Change | -166.17% | -63.85% | 73.56% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2023 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2023 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
33-0728374 | |
CY2023 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
2100 Powell Street | |
CY2023 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 720 | |
CY2023 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Emeryville | |
CY2023 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | |
CY2023 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
94608 | |
CY2023 | dei |
City Area Code
CityAreaCode
|
510 | |
CY2023 | dei |
Local Phone Number
LocalPhoneNumber
|
848-5100 | |
CY2023 | dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.001 par value | |
CY2023 | dei |
Trading Symbol
TradingSymbol
|
DVAX | |
CY2023 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2023 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2023 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001029142 | |
CY2023 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2023Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2023Q4 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent | |
CY2022Q4 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent | |
CY2023 | dei |
Document Type
DocumentType
|
10-K | |
CY2023 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2023 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-12-31 | |
CY2023 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
CY2023 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2023 | dei |
Entity File Number
EntityFileNumber
|
001-34207 | |
CY2023 | dei |
Entity Registrant Name
EntityRegistrantName
|
Dynavax Technologies Corp | |
CY2023 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2023 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
Yes | |
CY2023 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2023 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2023 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2023 | dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | |
CY2023 | dei |
Entity Small Business
EntitySmallBusiness
|
false | |
CY2023 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2023 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
true | |
CY2023 | dei |
Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
|
false | |
CY2023 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2023Q2 | dei |
Entity Public Float
EntityPublicFloat
|
900000000 | |
CY2024Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
130614772 | |
CY2023 | dei |
Auditor Firm
AuditorFirmId
|
42 | |
CY2023 | dei |
Auditor Name
AuditorName
|
Ernst & Young LLP | |
CY2023 | dei |
Auditor Location
AuditorLocation
|
San Francisco, California | |
CY2023 | dei |
Auditor Firm
AuditorFirmId
|
42 | |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
150279000 | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
202004000 | |
CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
592023000 | |
CY2022Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
422391000 | |
CY2023Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
12313000 | |
CY2022Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
0 | |
CY2023Q4 | us-gaap |
Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
|
40607000 | |
CY2022Q4 | us-gaap |
Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
|
145130000 | |
CY2023Q4 | us-gaap |
Other Receivables
OtherReceivables
|
3926000 | |
CY2022Q4 | us-gaap |
Other Receivables
OtherReceivables
|
2385000 | |
CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
53290000 | |
CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
59446000 | |
CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
18995000 | |
CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
85629000 | |
CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
859120000 | |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
916985000 | |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
37297000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
37596000 | |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
24287000 | |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
25745000 | |
CY2023Q4 | us-gaap |
Goodwill
Goodwill
|
2067000 | |
CY2022Q4 | us-gaap |
Goodwill
Goodwill
|
2006000 | |
CY2023Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
74325000 | |
CY2022Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
3518000 | |
CY2023Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-2108000 | |
CY2022Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-5438000 | |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-930584000 | |
CY2023Q4 | us-gaap |
Assets
Assets
|
997096000 | |
CY2022Q4 | us-gaap |
Assets
Assets
|
985850000 | |
CY2023Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5245000 | |
CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3211000 | |
CY2023Q4 | dvax |
Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
|
2982000 | |
CY2022Q4 | dvax |
Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
|
4775000 | |
CY2023Q4 | dvax |
Coalition For Epidemic Preparedness Innovations Accruals
CoalitionForEpidemicPreparednessInnovationsAccruals
|
0 | |
CY2022Q4 | dvax |
Coalition For Epidemic Preparedness Innovations Accruals
CoalitionForEpidemicPreparednessInnovationsAccruals
|
107738000 | |
CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
49448000 | |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
30719000 | |
CY2023Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
4520000 | |
CY2022Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
3631000 | |
CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
62195000 | |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
150074000 | |
CY2023Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
2802000 | |
CY2022Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
3922000 | |
CY2023Q4 | us-gaap |
Convertible Notes Payable
ConvertibleNotesPayable
|
222698000 | |
CY2022Q4 | us-gaap |
Convertible Notes Payable
ConvertibleNotesPayable
|
221578000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
29720000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
32801000 | |
CY2023Q4 | dvax |
Cepi Accrual Long Term
CepiAccrualLongTerm
|
60337000 | |
CY2022Q4 | dvax |
Cepi Accrual Long Term
CepiAccrualLongTerm
|
0 | |
CY2023Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
74000 | |
CY2022Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
384000 | |
CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
375024000 | |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
404837000 | |
CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
CY2022Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
278000000 | |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
278000000 | |
CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
129530000 | |
CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
129530000 | |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
127604000 | |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
127604000 | |
CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
130000 | |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
128000 | |
CY2023Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1554634000 | |
CY2022Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1510518000 | |
CY2021 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
922000 | |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-4367000 | |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-924195000 | |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
622072000 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
581013000 | |
CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
997096000 | |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
985850000 | |
CY2023 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
232284000 | |
CY2022 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
722683000 | |
CY2021 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
439442000 | |
CY2023 | us-gaap |
Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
|
50167000 | |
CY2022 | us-gaap |
Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
|
262153000 | |
CY2021 | us-gaap |
Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
|
173572000 | |
CY2023 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
54886000 | |
CY2022 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
46600000 | |
CY2021 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
32228000 | |
CY2023 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
152946000 | |
CY2022 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
131408000 | |
CY2021 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
100156000 | |
CY2023 | us-gaap |
Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
|
1000000 | |
CY2022 | us-gaap |
Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
|
1000000 | |
CY2021 | us-gaap |
Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
|
1000000 | |
CY2023 | dvax |
Bad Debt Expense
BadDebtExpense
|
12313000 | |
CY2022 | dvax |
Bad Debt Expense
BadDebtExpense
|
0 | |
CY2021 | dvax |
Bad Debt Expense
BadDebtExpense
|
0 | |
CY2023 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
269312000 | |
CY2022 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
439161000 | |
CY2021 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
304956000 | |
CY2023 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-37028000 | |
CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
283522000 | |
CY2021 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
134486000 | |
CY2023 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
31993000 | |
CY2022 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
7912000 | |
CY2021 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
140000 | |
CY2023 | us-gaap |
Interest Expense
InterestExpense
|
6757000 | |
CY2022 | us-gaap |
Interest Expense
InterestExpense
|
6732000 | |
CY2021 | us-gaap |
Interest Expense
InterestExpense
|
11176000 | |
CY2023 | us-gaap |
Sublease Income
SubleaseIncome
|
7577000 | |
CY2022 | us-gaap |
Sublease Income
SubleaseIncome
|
7685000 | |
CY2021 | us-gaap |
Sublease Income
SubleaseIncome
|
7735000 | |
CY2023 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | |
CY2022 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | |
CY2021 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-5232000 | |
CY2023 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | |
CY2022 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-1801000 | |
CY2021 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
49354000 | |
CY2023 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-152000 | |
CY2022 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
111000 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
294299000 | |
CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
77521000 | |
CY2023 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2022000 | |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1143000 | |
CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
808000 | |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6389000 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
293156000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
76713000 | |
CY2023 | dvax |
Undistributed Earnings Allocated To Participating Securities
UndistributedEarningsAllocatedToParticipatingSecurities
|
0 | |
CY2022 | dvax |
Undistributed Earnings Allocated To Participating Securities
UndistributedEarningsAllocatedToParticipatingSecurities
|
283000 | |
CY2021 | dvax |
Undistributed Earnings Allocated To Participating Securities
UndistributedEarningsAllocatedToParticipatingSecurities
|
4569000 | |
CY2023 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-6389000 | |
CY2022 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
292873000 | |
CY2021 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
72144000 | |
CY2023 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.05 | |
CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
2.32 | |
CY2021 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.62 | |
CY2023 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.05 | |
CY2022 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
1.97 | |
CY2021 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.57 | |
CY2023 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
128733000 | |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
126398000 | |
CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
116264000 | |
CY2023 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
128733000 | |
CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
150797000 | |
CY2021 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
133006000 | |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6389000 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
293156000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
76713000 | |
CY2023 | dvax |
Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
|
2251000 | |
CY2022 | dvax |
Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
|
-1407000 | |
CY2021 | dvax |
Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
|
-30000 | |
CY2023 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
1079000 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-1765000 | |
CY2021 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-2509000 | |
CY2023 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
3330000 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-3172000 | |
CY2021 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-2539000 | |
CY2023 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-3059000 | |
CY2022 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
289984000 | |
CY2021 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
74174000 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
58693000 | |
CY2021 | dvax |
Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
|
6684000 | |
CY2021 | dvax |
Issuance Of Common Stock Upon Release Of Restricted Stock Awards
IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards
|
-107000 | |
CY2021 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
841000 | |
CY2021 | dvax |
Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
|
59888000 | |
CY2021 | dvax |
Issuance Of Common Stock Net Of Issuance Costs In Conjunction With An Underwritten Public Offering And An At Market Sales Agreement
IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement
|
28156000 | |
CY2021 | dvax |
Issuance Of Capped Call Options See Note10
IssuanceOfCappedCallOptionsSeeNote10
|
-27240000 | |
CY2021 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
21285000 | |
CY2021 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-2539000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
76713000 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
222374000 | |
CY2022 | dvax |
Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
|
9640000 | |
CY2022 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
1430000 | |
CY2022 | dvax |
Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
|
24670000 | |
CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
32915000 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-3172000 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
293156000 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
581013000 | |
CY2023 | dvax |
Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
|
6361000 | |
CY2023 | dvax |
Issuance Of Common Stock Upon Release Of Restricted Stock Awards Net Of Statutory Tax Withholdings
IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings
|
-6370000 | |
CY2023 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
1535000 | |
CY2023 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
42592000 | |
CY2023 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
3330000 | |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6389000 | |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
622072000 | |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6389000 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
293156000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
76713000 | |
CY2023 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
4342000 | |
CY2022 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
3812000 | |
CY2021 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
4296000 | |
CY2023 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
2934000 | |
CY2022 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
2856000 | |
CY2021 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
2762000 | |
CY2023 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
0 | |
CY2022 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
34288000 | |
CY2021 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
2588000 | |
CY2023 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
16555000 | |
CY2022 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
4181000 | |
CY2021 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-470000 | |
CY2023 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | |
CY2022 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | |
CY2021 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-5232000 | |
CY2023 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | |
CY2022 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-1801000 | |
CY2021 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
49354000 | |
CY2023 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
42592000 | |
CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
32915000 | |
CY2021 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
21285000 | |
CY2023 | dvax |
Non Cash Interest Expense
NonCashInterestExpense
|
1120000 | |
CY2022 | dvax |
Non Cash Interest Expense
NonCashInterestExpense
|
1088000 | |
CY2021 | dvax |
Non Cash Interest Expense
NonCashInterestExpense
|
1608000 | |
CY2023 | us-gaap |
Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
|
1000000 | |
CY2022 | us-gaap |
Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
|
1000000 | |
CY2021 | us-gaap |
Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
|
1000000 | |
CY2023 | dvax |
Bad Debt Expense
BadDebtExpense
|
12313000 | |
CY2022 | dvax |
Bad Debt Expense
BadDebtExpense
|
0 | |
CY2021 | dvax |
Bad Debt Expense
BadDebtExpense
|
0 | |
CY2023 | us-gaap |
Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
|
-43268000 | |
CY2022 | us-gaap |
Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
|
15699000 | |
CY2021 | us-gaap |
Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
|
109155000 | |
CY2023 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-3909000 | |
CY2022 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
32399000 | |
CY2021 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
234000 | |
CY2023 | dvax |
Increase Decrease In Prepaid Manufacturing
IncreaseDecreaseInPrepaidManufacturing
|
-0 | |
CY2022 | dvax |
Increase Decrease In Prepaid Manufacturing
IncreaseDecreaseInPrepaidManufacturing
|
-159655000 | |
CY2021 | dvax |
Increase Decrease In Prepaid Manufacturing
IncreaseDecreaseInPrepaidManufacturing
|
130232000 | |
CY2023 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
4673000 | |
CY2022 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
11865000 | |
CY2021 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
64558000 | |
CY2023 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-570000 | |
CY2022 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-87000 | |
CY2021 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-175000 | |
CY2023 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1952000 | |
CY2022 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
691000 | |
CY2021 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-767000 | |
CY2023 | dvax |
Increase Decrease In Cepi Accrual
IncreaseDecreaseInCepiAccrual
|
0 | |
CY2022 | dvax |
Increase Decrease In Cepi Accrual
IncreaseDecreaseInCepiAccrual
|
-21110000 | |
CY2021 | dvax |
Increase Decrease In Cepi Accrual
IncreaseDecreaseInCepiAccrual
|
128848000 | |
CY2023 | dvax |
Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
|
3629000 | |
CY2022 | dvax |
Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
|
3125000 | |
CY2021 | dvax |
Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
|
3234000 | |
CY2023 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
0 | |
CY2022 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-349864000 | |
CY2021 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
311652000 | |
CY2023 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
19809000 | |
CY2022 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-24788000 | |
CY2021 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
39725000 | |
CY2023 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
100563000 | |
CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
62716000 | |
CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
335528000 | |
CY2023 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
636921000 | |
CY2022 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
632306000 | |
CY2021 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
164928000 | |
CY2023 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
486097000 | |
CY2022 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
322450000 | |
CY2021 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
187630000 | |
CY2023 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
4104000 | |
CY2022 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
7139000 | |
CY2021 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
9477000 | |
CY2023 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
1000000 | |
CY2022 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
1000000 | |
CY2021 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
1000000 | |
CY2023 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-153928000 | |
CY2022 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-315995000 | |
CY2021 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
14225000 | |
CY2023 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | |
CY2022 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | |
CY2021 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
28156000 | |
CY2023 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
0 | |
CY2022 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
0 | |
CY2021 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
219822000 | |
CY2023 | dvax |
Payments For Purchase Of Capped Call Options
PaymentsForPurchaseOfCappedCallOptions
|
0 | |
CY2022 | dvax |
Payments For Purchase Of Capped Call Options
PaymentsForPurchaseOfCappedCallOptions
|
0 | |
CY2021 | dvax |
Payments For Purchase Of Capped Call Options
PaymentsForPurchaseOfCappedCallOptions
|
27240000 | |
CY2023 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
0 | |
CY2022 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
0 | |
CY2021 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
190194000 | |
CY2023 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
0 | |
CY2022 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
8455000 | |
CY2021 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
17814000 | |
CY2023 | dvax |
Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
|
6360000 | |
CY2022 | dvax |
Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
|
9639000 | |
CY2021 | dvax |
Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
|
6577000 | |
CY2023 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
1535000 | |
CY2022 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
1431000 | |
CY2021 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
841000 | |
CY2023 | dvax |
Payments For Taxes Related To Net Share Settlement Of Rsus
PaymentsForTaxesRelatedToNetShareSettlementOfRsus
|
6509000 | |
CY2022 | dvax |
Payments For Taxes Related To Net Share Settlement Of Rsus
PaymentsForTaxesRelatedToNetShareSettlementOfRsus
|
0 | |
CY2021 | dvax |
Payments For Taxes Related To Net Share Settlement Of Rsus
PaymentsForTaxesRelatedToNetShareSettlementOfRsus
|
0 | |
CY2023 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1386000 | |
CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
19525000 | |
CY2021 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
55776000 | |
CY2023 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
324000 | |
CY2022 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-443000 | |
CY2021 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-1431000 | |
CY2023 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-51655000 | |
CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-234197000 | |
CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
404098000 | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
202211000 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
436408000 | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
32310000 | |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
150556000 | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
202211000 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
436408000 | |
CY2023 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
2014000 | |
CY2022 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
2208000 | |
CY2021 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
1312000 | |
CY2023 | us-gaap |
Interest Paid Net
InterestPaidNet
|
5638000 | |
CY2022 | us-gaap |
Interest Paid Net
InterestPaidNet
|
5638000 | |
CY2021 | us-gaap |
Interest Paid Net
InterestPaidNet
|
9815000 | |
CY2023 | dvax |
Reclassification Of Contract Asset From Other Current Assets To Other Assets
ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
|
71307000 | |
CY2022 | dvax |
Reclassification Of Contract Asset From Other Current Assets To Other Assets
ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
|
0 | |
CY2021 | dvax |
Reclassification Of Contract Asset From Other Current Assets To Other Assets
ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
|
0 | |
CY2023 | dvax |
Reclassification Of Cepi Accrual To Cepi Accrual Long Term
ReclassificationOfCepiAccrualToCepiAccrualLongTerm
|
-60337000 | |
CY2022 | dvax |
Reclassification Of Cepi Accrual To Cepi Accrual Long Term
ReclassificationOfCepiAccrualToCepiAccrualLongTerm
|
0 | |
CY2021 | dvax |
Reclassification Of Cepi Accrual To Cepi Accrual Long Term
ReclassificationOfCepiAccrualToCepiAccrualLongTerm
|
0 | |
CY2023Q4 | dvax |
Advance Payment From Customer
AdvancePaymentFromCustomer
|
-47401000 | |
CY2022Q4 | dvax |
Advance Payment From Customer
AdvancePaymentFromCustomer
|
0 | |
CY2021Q4 | dvax |
Advance Payment From Customer
AdvancePaymentFromCustomer
|
0 | |
CY2023 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
299000 | |
CY2022 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
1015000 | |
CY2021 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
591000 | |
CY2023 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
1332000 | |
CY2022 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
2848000 | |
CY2021 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
2468000 | |
CY2023 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management’s estimates are based on historical information available as of the date of the consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> | |
CY2023 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
1100000 | |
CY2022 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
-1800000 | |
CY2021 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
-2500000 | |
CY2023 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
-100000 | |
CY2022 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
100000 | |
CY2021 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
900000 | |
CY2023 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
CY2023 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our policy is to invest cash in institutional money market funds and marketable securities of the U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We have not experienced any significant losses on our cash equivalents and marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our accounts receivable balance consists, primarily, of amounts due from product sales. Accounts receivable are recorded net of reserves for chargebacks, distribution fees, trade discounts and doubtful accounts. We estimate our allowance for doubtful accounts based on</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an evaluation of the aging of our receivables. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. During the year ended December 31, 2023, we recorded an allowance for doubtful accounts of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was determined by assessing changes in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biological E. Limited's (“Bio E”) credit risk, contemplation of ongoing negotiations relating to Bio E Amendment No. 3 (See Note 9), and Bio E's dependence on cash collections from the Government of India, which have been delayed and significantly reduced in connection with the overall reduction in demand for CORBEVAX from the Government of India. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customers collectively represented approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our HEPLISAV-B trade receivable balance, respectively. As of December 31, 2023, we had no CpG 1018 adjuvant trade receivable balance. As of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer represented approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our CpG 1018 adjuvant trade receivable balance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates will require approval from the United States Food and Drug Administration ("FDA") and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our product candidates will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on our business and may impact our business in the future. In addition, after the approval of HEPLISAV-B by the FDA, there is still an ongoing risk of adverse events that did not appear during the drug approval process that could affect our authorizations in the future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of product candidates, product liability, the volatility of our stock price and the need to obtain additional financing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our long-lived assets located in the United States as of December 31, 2023 and 2022, represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our total assets, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">respectively, and the remaining long-lived assets were located in Germany.</span></p> | |
CY2023Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
12300000 | |
CY2023Q4 | dvax |
Percentage Of Long Lived Assets
PercentageOfLongLivedAssets
|
0.31 | |
CY2022Q4 | dvax |
Percentage Of Long Lived Assets
PercentageOfLongLivedAssets
|
0.34 | |
CY2023 | dvax |
Inventory Write Offs Recognized
InventoryWriteOffsRecognized
|
34300000 | |
CY2023 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
CY2023 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | |
CY2023Q4 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
|
440131000 | |
CY2023 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
|
0 | |
CY2022 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
|
0 | |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
150279000 | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
202004000 | |
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
436189000 | |
CY2023Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
277000 | |
CY2022Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
207000 | |
CY2021Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
219000 | |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
150556000 | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
202211000 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
436408000 | |
CY2023Q4 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
440104000 | |
CY2023Q4 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
|
151046000 | |
CY2022Q4 | dvax |
Computer Equipment Gross
ComputerEquipmentGross
|
4720000 | |
CY2023Q4 | us-gaap |
Furniture And Fixtures Gross
FurnitureAndFixturesGross
|
2467000 | |
CY2022Q4 | us-gaap |
Furniture And Fixtures Gross
FurnitureAndFixturesGross
|
2464000 | |
CY2023Q4 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
37201000 | |
CY2022Q4 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
28822000 | |
CY2023Q4 | us-gaap |
Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
|
5822000 | |
CY2023Q4 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
151919000 | |
CY2023Q4 | us-gaap |
Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
|
591177000 | |
CY2023Q4 | us-gaap |
Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
|
592023000 | |
CY2023 | us-gaap |
Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
|
0 | |
CY2022 | us-gaap |
Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
|
0 | |
CY2023Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
27256000 | |
CY2022Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
25517000 | |
CY2023Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
18954000 | |
CY2022Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
23934000 | |
CY2023Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
7080000 | |
CY2022Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
9995000 | |
CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
53290000 | |
CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
59446000 | |
CY2023Q4 | us-gaap |
Machinery And Equipment Gross
MachineryAndEquipmentGross
|
15752000 | |
CY2022Q4 | us-gaap |
Machinery And Equipment Gross
MachineryAndEquipmentGross
|
15139000 | |
CY2023Q4 | dvax |
Laboratory Equipment Gross
LaboratoryEquipmentGross
|
2827000 | |
CY2022Q4 | dvax |
Laboratory Equipment Gross
LaboratoryEquipmentGross
|
2360000 | |
CY2023Q4 | dvax |
Computer Equipment Gross
ComputerEquipmentGross
|
5060000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
|
11613000 | |
CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
69129000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
65118000 | |
CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
31832000 | |
CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
27522000 | |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
37297000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
37596000 | |
CY2023 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
4300000 | |
CY2022 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
3800000 | |
CY2021 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
4300000 | |
CY2023Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
17069000 | |
CY2022Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
14261000 | |
CY2023Q4 | dvax |
Revenue Reserve Accrual Current
RevenueReserveAccrualCurrent
|
21004000 | |
CY2022Q4 | dvax |
Revenue Reserve Accrual Current
RevenueReserveAccrualCurrent
|
10552000 | |
CY2023Q4 | dvax |
Accrued Inventory
AccruedInventory
|
4456000 | |
CY2022Q4 | dvax |
Accrued Inventory
AccruedInventory
|
2209000 | |
CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
6919000 | |
CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
3697000 | |
CY2023Q4 | dvax |
Accrued Research And Development Expenses And Accrued Liabilities Current
AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent
|
49448000 | |
CY2022Q4 | dvax |
Accrued Research And Development Expenses And Accrued Liabilities Current
AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent
|
30719000 | |
CY2023 | us-gaap |
Lease Expiration Date1
LeaseExpirationDate1
|
2031-03-31 | |
CY2023 | us-gaap |
Lessee Operating Sublease Option To Extend
LesseeOperatingSubleaseOptionToExtend
|
The subtenant has no option to extend the sublease term. | |
CY2023 | us-gaap |
Sublease Income
SubleaseIncome
|
7600000 | |
CY2022 | us-gaap |
Sublease Income
SubleaseIncome
|
7700000 | |
CY2021 | us-gaap |
Sublease Income
SubleaseIncome
|
7700000 | |
CY2023Q4 | dvax |
Percentage Of Excess Rent Paid To Landlord
PercentageOfExcessRentPaidToLandlord
|
0.50 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
6215000 | |
CY2023 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
5563000 | |
CY2022 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
6222000 | |
CY2021 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
6265000 | |
CY2023 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
7200000 | |
CY2022 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
6800000 | |
CY2021 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
7000000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
4496000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
3631000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
29720000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
32801000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
34216000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
36432000 | |
CY2023Q4 | dvax |
Lessor Sublease Rentals Payments To Be Received Next Twelve Months
LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths
|
5684000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
7605000 | |
CY2023Q4 | dvax |
Lessor Sublease Rentals Payments To Be Received Due Year Two
LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo
|
5854000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
6980000 | |
CY2023Q4 | dvax |
Lessor Sublease Rentals Payments To Be Received Due Year Three
LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree
|
6030000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
6122000 | |
CY2023Q4 | dvax |
Lessor Sublease Rentals Payments To Be Received Due Year Four
LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour
|
6211000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
6052000 | |
CY2023Q4 | dvax |
Lessor Sublease Rentals Payments To Be Received Due Year Five
LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive
|
6397000 | |
CY2023 | us-gaap |
Debt Instrument Convertible Threshold Trading Days
DebtInstrumentConvertibleThresholdTradingDays
|
20 | |
CY2023Q4 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
330100000 | |
CY2023Q4 | dvax |
Lessor Sublease Rentals Payments To Be Received Due Thereafter
LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter
|
15103000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
15062000 | |
CY2023Q4 | dvax |
Lessor Sublease Rentals Payments To Be Received Due
LessorSubleaseRentalsPaymentsToBeReceivedDue
|
45279000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
48036000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
13820000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
34216000 | |
CY2023Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P6Y8M12D | |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P7Y7M6D | |
CY2023Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.101 | |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.101 | |
CY2023Q4 | us-gaap |
Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
|
18866000 | |
CY2023Q4 | us-gaap |
Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
|
11983000 | |
CY2023Q4 | us-gaap |
Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
|
12516000 | |
CY2023Q4 | us-gaap |
Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
|
0 | |
CY2023Q4 | us-gaap |
Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
|
0 | |
CY2023Q4 | us-gaap |
Purchase Obligation Due After Fifth Year
PurchaseObligationDueAfterFifthYear
|
0 | |
CY2023Q4 | us-gaap |
Purchase Obligation
PurchaseObligation
|
43365000 | |
CY2023 | dvax |
Description Of Avecia Supply Agreement
DescriptionOfAveciaSupplyAgreement
|
On September 7, 2023 (the “Effective Date”), we entered into an agreement (the “Avecia Supply Agreement”) with Nitto Denko Avecia Inc. (“Avecia”) for the manufacture and supply of our CpG 1018 adjuvant using a specific production process. Under the Avecia Supply Agreement, Avecia has agreed to produce and supply to us quantities of CpG 1018 adjuvant ordered by us after the Effective Date. Subject to certain conditions in the Avecia Supply Agreement, we are obligated to purchase all of our annual volume requirements of CpG 1018 adjuvant from Avecia up to a specified production capacity. We may alternatively order CpG 1018 adjuvant produced using a different production process pursuant to the existing supply agreement between us and Avecia dated October 1, 2012 (the “2012 Agreement”). As of December 31, 2023, our aggregate minimum commitment for the supply of CpG 1018 adjuvant under the Avecia Supply Agreement was $7.4 million within the next 12 months. As of December 31, 2022, we had no non-cancelable purchase and other commitments for the supply of CpG 1018 adjuvant. | |
CY2023Q4 | dvax |
Aggregate Minimum Commitment
AggregateMinimumCommitment
|
7400000 | |
CY2023Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
12300000 | |
CY2023Q2 | dvax |
Prepayment Of Advance Payment
PrepaymentOfAdvancePayment
|
13500000 | |
CY2023Q2 | dvax |
Repayment Of Advance From Customer
RepaymentOfAdvanceFromCustomer
|
47400000 | |
CY2023Q3 | us-gaap |
Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Modification Of Contract
ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract
|
33700000 | |
CY2023 | us-gaap |
Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
|
5636000 | |
CY2022 | us-gaap |
Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
|
5638000 | |
CY2023 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
1121000 | |
CY2022 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
1094000 | |
CY2023 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
6757000 | |
CY2022 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
6732000 | |
CY2023 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
232284000 | |
CY2022 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
722683000 | |
CY2021 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
439442000 | |
CY2023 | us-gaap |
Contract With Customer Asset Change In Method Credit Loss Expense Reversal
ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal
|
71307000 | |
CY2023Q4 | us-gaap |
Contract With Customer Asset Accumulated Allowance For Credit Loss Noncurrent
ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent
|
71307000 | |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6389000 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
293156000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
76713000 | |
CY2022 | us-gaap |
Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
|
-283000 | |
CY2021 | us-gaap |
Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
|
-4569000 | |
CY2023 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-6389000 | |
CY2022 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
292873000 | |
CY2021 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
72144000 | |
CY2023 | dvax |
Addition Of Undistributed Earnings Allocated To Series B And Warrants
AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
|
0 | |
CY2022 | dvax |
Addition Of Undistributed Earnings Allocated To Series B And Warrants
AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
|
283000 | |
CY2021 | dvax |
Addition Of Undistributed Earnings Allocated To Series B And Warrants
AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
|
4569000 | |
CY2023 | dvax |
Deduction Of Undistributed Earnings Allocated To Series B And Warrants
DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
|
0 | |
CY2022 | dvax |
Deduction Of Undistributed Earnings Allocated To Series B And Warrants
DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
|
0 | |
CY2021 | dvax |
Deduction Of Undistributed Earnings Allocated To Series B And Warrants
DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
|
-4190000 | |
CY2023 | us-gaap |
Interest Expense Medium Term Notes
InterestExpenseMediumTermNotes
|
0 | |
CY2022 | us-gaap |
Interest Expense Medium Term Notes
InterestExpenseMediumTermNotes
|
5044000 | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
16291000 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1982000 | |
CY2023 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
11.17 | |
CY2023 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
850000 | |
CY2021 | us-gaap |
Interest Expense Medium Term Notes
InterestExpenseMediumTermNotes
|
3168000 | |
CY2023 | dvax |
Fair Value Adjustments Of Warrants
FairValueAdjustmentsOfWarrants
|
-0 | |
CY2022 | dvax |
Fair Value Adjustments Of Warrants
FairValueAdjustmentsOfWarrants
|
-1801000 | |
CY2021 | dvax |
Fair Value Adjustments Of Warrants
FairValueAdjustmentsOfWarrants
|
0 | |
CY2023 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-6389000 | |
CY2022 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
296399000 | |
CY2021 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
75691000 | |
CY2023 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
128733000 | |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
126398000 | |
CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
116264000 | |
CY2023 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
0 | |
CY2022 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2774000 | |
CY2021 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3075000 | |
CY2023 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
0 | |
CY2022 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
21543000 | |
CY2021 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
13667000 | |
CY2023 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
0 | |
CY2022 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
82000 | |
CY2021 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
0 | |
CY2023 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
128733000 | |
CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
150797000 | |
CY2021 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
133006000 | |
CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
129530228 | |
CY2022Q2 | dvax |
Increase In Number Of Employee Stock Purchase Plan Shares Authorized For Issuance
IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance
|
15000000 | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
9339000 | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
10.7 | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P4Y7M9D | |
CY2023 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
7.48 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
90000 | |
CY2023 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
10.93 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
261000 | |
CY2023 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
21.39 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
10120000 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
10.78 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P4Y2M4D | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
37388000 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
9976000 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
10.77 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P4Y1M24D | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
37024000 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
7014000 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
10.4 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P3Y6M | |
CY2023Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
29613000 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
42592000 | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
32915000 | |
CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
21285000 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
42592000 | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
32915000 | |
CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
21285000 | |
CY2021Q2 | dvax |
Increase In Number Of Employee Stock Purchase Plan Shares Authorized For Issuance
IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance
|
1000000 | |
CY2023 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
1300000 | |
CY2022 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
900000 | |
CY2021 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
300000 | |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-6275000 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
292460000 | |
CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
75954000 | |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
1908000 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
1839000 | |
CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
1567000 | |
CY2023 | dvax |
Income Loss From Continuing Operations Before Income Taxes
IncomeLossFromContinuingOperationsBeforeIncomeTaxes
|
-4367000 | |
CY2022 | dvax |
Income Loss From Continuing Operations Before Income Taxes
IncomeLossFromContinuingOperationsBeforeIncomeTaxes
|
294299000 | |
CY2021 | dvax |
Income Loss From Continuing Operations Before Income Taxes
IncomeLossFromContinuingOperationsBeforeIncomeTaxes
|
77521000 | |
CY2023 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
-178000 | |
CY2022 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
-165000 | |
CY2021 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
345000 | |
CY2023 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
1533000 | |
CY2022 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
897000 | |
CY2021 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
260000 | |
CY2023 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
667000 | |
CY2022 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
411000 | |
CY2021 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
203000 | |
CY2023 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
2022000 | |
CY2022 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
1143000 | |
CY2021 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
808000 | |
CY2023 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
0 | |
CY2022 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
0 | |
CY2021 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
0 | |
CY2023 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
0 | |
CY2022 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
0 | |
CY2021 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
0 | |
CY2023 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
0 | |
CY2022 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
0 | |
CY2021 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
0 | |
CY2023 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | |
CY2022 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | |
CY2021 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | |
CY2023 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2022000 | |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1143000 | |
CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
808000 | |
CY2023 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-917000 | |
CY2022 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
61775000 | |
CY2021 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
16397000 | |
CY2023 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
574000 | |
CY2022 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-2942000 | |
CY2021 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
3576000 | |
CY2023 | dvax |
Income Tax Reconciliation Tax Credit
IncomeTaxReconciliationTaxCredit
|
2050000 | |
CY2022 | dvax |
Income Tax Reconciliation Tax Credit
IncomeTaxReconciliationTaxCredit
|
3246000 | |
CY2021 | dvax |
Income Tax Reconciliation Tax Credit
IncomeTaxReconciliationTaxCredit
|
982000 | |
CY2023 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
334000 | |
CY2022 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
586000 | |
CY2021 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
424000 | |
CY2023 | dvax |
Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
|
830000 | |
CY2022 | dvax |
Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
|
-473000 | |
CY2021 | dvax |
Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
|
131000 | |
CY2023 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
1466000 | |
CY2022 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-324000 | |
CY2021 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-86847000 | |
CY2023 | dvax |
Section162 M Limitation
Section162MLimitation
|
1963000 | |
CY2022 | dvax |
Section162 M Limitation
Section162MLimitation
|
1779000 | |
CY2021 | dvax |
Section162 M Limitation
Section162MLimitation
|
1241000 | |
CY2023 | dvax |
Income Tax Rate Reconciliation Mark To Market Of Warrants
IncomeTaxRateReconciliationMarkToMarketOfWarrants
|
0 | |
CY2022 | dvax |
Income Tax Rate Reconciliation Mark To Market Of Warrants
IncomeTaxRateReconciliationMarkToMarketOfWarrants
|
-378000 | |
CY2021 | dvax |
Income Tax Rate Reconciliation Mark To Market Of Warrants
IncomeTaxRateReconciliationMarkToMarketOfWarrants
|
10364000 | |
CY2023 | dvax |
Net Operating Loss And Tax Credit Limitations
NetOperatingLossAndTaxCreditLimitations
|
0 | |
CY2022 | dvax |
Net Operating Loss And Tax Credit Limitations
NetOperatingLossAndTaxCreditLimitations
|
-56908000 | |
CY2021 | dvax |
Net Operating Loss And Tax Credit Limitations
NetOperatingLossAndTaxCreditLimitations
|
56459000 | |
CY2023 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
-518000 | |
CY2022 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
879000 | |
CY2021 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
-290000 | |
CY2023 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
340000 | |
CY2022 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
395000 | |
CY2021 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
335000 | |
CY2023 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2022000 | |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1143000 | |
CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
808000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
96336000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
113228000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
34940000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
33444000 | |
CY2023Q4 | dvax |
Deferredtaxassetsoperatinglosscarryforwardscapitalization
Deferredtaxassetsoperatinglosscarryforwardscapitalization
|
22556000 | |
CY2022Q4 | dvax |
Deferredtaxassetsoperatinglosscarryforwardscapitalization
Deferredtaxassetsoperatinglosscarryforwardscapitalization
|
15308000 | |
CY2023Q4 | dvax |
Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
|
8868000 | |
CY2022Q4 | dvax |
Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
|
9530000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
|
10572000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
|
7780000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
15808000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
9089000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
348000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
337000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
189428000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
188716000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
180387000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
178920000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
9041000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
9796000 | |
CY2023Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
2667000 | |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
2916000 | |
CY2023Q4 | dvax |
Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
|
6345000 | |
CY2022Q4 | dvax |
Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
|
6785000 | |
CY2023Q4 | us-gaap |
Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
|
29000 | |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
|
95000 | |
CY2023Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
9041000 | |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
9796000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | |
CY2023 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
1500000 | |
CY2022 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
300000 | |
CY2023Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
353500000 | |
CY2023Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
12100000 | |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
11300000 | |
CY2023Q4 | us-gaap |
Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
|
0 | |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
11339000 | |
CY2021Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
5615000 | |
CY2023 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
762000 | |
CY2022 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
670000 | |
CY2023 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
|
0 | |
CY2022 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
|
0 | |
CY2023 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
0 | |
CY2022 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
5054000 | |
CY2023 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
|
0 | |
CY2022 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
|
0 | |
CY2023 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
|
0 | |
CY2022 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
|
0 | |
CY2022 | us-gaap |
Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
|
0 | |
CY2023Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
12101000 | |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
11339000 | |
CY2023 | us-gaap |
Unrecognized Tax Benefits Interest On Income Taxes Expense
UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
|
0 | |
CY2023 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
|
0 | |
CY2022 | us-gaap |
Unrecognized Tax Benefits Interest On Income Taxes Expense
UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
|
0 | |
CY2022 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
|
0 |